Among the manifold effects of vagus nerve stimulation (VNS) delivered as an add-on treatment to patients with drug-resistant epilepsy, a moderate loss of body weight has been observed in some individuals. We have now investigated this effect in rats. Exposure of rats to VNS for 4 weeks reduced feed conversion efficiency as well as body weight gain (by ~25%) and the amount of mesenteric adipose tissue (by ~45%) in comparison with those in sham-operated control animals. A pair-fed experiment showed that both lower dietary intake and increase energy expenditure independently contributed to the reduction of body weight and mesenteric adipose tissue. Moreover, VNS increased the level of non-esterified fatty acids in plasma and mesenteric adipose tissue by ~50 and 80%, respectively, without affecting that in the liver. In addition, VNS reduced the amounts of endocannabinoids and increased N-palmitoylethanolamide, an endogenous ligand of the transcription factor PPARα (peroxisome proliferator–activated receptor α) in mesenteric adipose tissue but not in the hypothalamus. These effects were accompanied by increased expression of the gene for brain-derived neurotrophic factor (BDNF) in the hypothalamus and up-regulation of the abundance of PPARα in the liver. Our results suggest that the reduction in body fat induced by VNS in rats may result from the action of both central and peripheral mediators. The reduced feed conversion efficiency associated with VNS may be mediated by hypothalamic BDNF, down-regulation of endocannabinoid tone in mesenteric adipose tissue and a PPARα-dependent increase in fatty acid oxidation in the liver, which in concerted action may account for the anorexic effect and increased energy expenditure.
References
[1]
Ben-Menachem E (2002) Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 1: 477–482.
[2]
Burneo JG, Faught E, Knowlton R, Morawetz R, Kuzniecky R (2002) Weight loss associated with vagus nerve stimulation. Neurology 59: 463–464.
[3]
Ramsay RE, Uthman BM, Augustinsson LE, Upton AR, Naritoku D, et al. (1994) Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group. Epilepsia 35: 627–636.
[4]
Abubakr A, Wambacq I (2008) Long-term outcome of vagus nerve stimulation therapy in patients with refractory epilepsy. J Clin Neurosci 15: 127–129.
[5]
Koren MS, Holmes MD (2006) Vagus nerve stimulation does not lead to significant changes in body weight in patients with epilepsy. Epilepsy Behav 8: 246–249.
[6]
Pardo JV, Sheikh SA, Kuskowski MA, Surerus-Johnson C, Hagen MC, et al. (2007) Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. Int J Obes 31: 1756–1759.
[7]
Bugajski AJ, Gil K, Ziomber A, Zurowski D, Zaraska W, et al. (2007) Effect of long-term vagal stimulation on food intake and body weight during diet induced obesity in rats. J Physiol Pharmacol 58 Suppl 15–12.
[8]
Sobocki J, Fourtanier G, Estany J, Otal P (2006) Does vagal nerve stimulation affect body composition and metabolism? Experimental study of a new potential technique in bariatric surgery. Surgery 139: 209–216.
[9]
Biggio F, Gorini G, Utzeri C, Olla P, Marrosu F, et al.. (2009) Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. Int J Neuropsychopharmacol 1–13.
[10]
Follesa P, Biggio F, Gorini G, Caria S, Talani G, et al. (2007) Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain. Brain Res 1179: 28–34.
[11]
Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677–736.
[12]
Cao L, Lin EJ, Cahill MC, Wang C, Liu X, et al. (2009) Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med 15: 447–454.
[13]
Wisse BE, Schwartz MW (2003) The skinny on neurotrophins. Nat Neurosci 6: 655–656.
[14]
Ono M, Ichihara J, Nonomura T, Itakura Y, Taiji M, et al. (1997) Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice. Biochem Biophys Res Commun 238: 633–637.
[15]
Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, et al. (1999) Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96: 15239–15244.
[16]
Gaetani S, Kaye WH, Cuomo V, Piomelli D (2008) Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 13: e42–48.
[17]
Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, et al. (2008) Biological functions and metabolism of oleoylethanolamide. Lipids 43: 887–894.
[18]
Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825.
[19]
Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, et al. (1998) Trick or treat from food endocannabinoids? Nature 396: 636–637.
[20]
Kirkham TC, Tucci SA (2006) Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 5: 272–292.
[21]
Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, et al. (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908–914.
[22]
Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423–431.
[23]
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838–2843.
[24]
Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497–509.
[25]
Banni S, Carta G, Angioni E, Murru E, Scanu P, et al. (2001) Distribution of conjugated linoleic acid and metabolites in different lipid fractions in the rat liver. J Lipid Res 42: 1056–1061.
[26]
Banni S, Carta G, Contini MS, Angioni E, Deiana M, et al. (1996) Characterization of Conjugated Diene Fatty Acids in Milk, Dairy Products, and Lamb Tissues. J Nutr Biochem 7: 150–155.
[27]
Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, et al. (2009) Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24: 830–840.
[28]
Chiang SP, Lowry OH, Senturia BH (1955) Micro-chemical studies on normal cerumen I. The lipid and protein content of normal cerumen as affected by age and sex. The Laryngoscope 65: 927–934.
[29]
Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, et al. (2011) Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab 8: 51.
[30]
Lubin FD, Roth TL, Sweatt JD (2008) Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci 28: 10576–10586.
[31]
Marrosu F, Maleci A, Cocco E, Puligheddu M, Barberini L, et al. (2007) Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Mult Scler 13: 1200–1202.
[32]
Marrosu F, Maleci A, Cocco E, Puligheddu M, Marrosu MG (2005) Vagal nerve stimulation effects on cerebellar tremor in multiple sclerosis. Neurology 65: 490.
[33]
Schwartz GJ (2000) The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16: 866–873.
[34]
Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425: 90–93.
[35]
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15–19.
[36]
Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ (2010) Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J Physiol Gastrointest Liver Physiol 299: G63–69.
[37]
Di Marzo V (2008) Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Nat Clin Pract Cardiovasc Med 5: 610–612.
[38]
Meregnani J, Clarencon D, Vivier M, Peinnequin A, Mouret C, et al. (2011) Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Auton Neurosci 160: 82–89.
[39]
Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, et al. (2003) Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6: 736–742.
[40]
Wang C, Bomberg E, Billington C, Levine A, Kotz CM (2007) Brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus increases energy expenditure by elevating metabolic rate. Am J Physiol Regul Integr Comp Physiol 293: R992–1002.
[41]
Wang C, Bomberg E, Billington CJ, Levine AS, Kotz CM (2010) Brain-derived neurotrophic factor (BDNF) in the hypothalamic ventromedial nucleus increases energy expenditure. Brain Res 1336: 66–77.
[42]
Vander Tuig JG, Knehans AW, Romsos DR (1982) Reduced sympathetic nervous system activity in rats with ventromedial hypothalamic lesions. Life Sci 30: 913–920.
[43]
Yoshida T, Bray GA (1984) Catecholamine turnover in rats with ventromedial hypothalamic lesions. Am J Physiol 246: R558–565.
[44]
de Oliveira LCS, Bonagamba LGH, Machado BH (2007) Noradrenergic inhibitory modulation in the caudal commissural NTS of the pressor response to chemoreflex activation in awake rats. Aut Neurosci 136: 63–68.
[45]
Aston-Jones G, Rajkowski J, Cohen J (1999) Role of locus coeruleus in attention and behavioral flexibility. Biol Psychiatry 46: 1309–1320.
[46]
Morimoto C, Tsujita T, Okuda H (1997) Norepinephrine-induced lipolysis in rat fat cells from visceral and subcutaneous sites: Role of hormone-sensitive lipase and lipid droplets. J Lipid Res 38: 132–138.
